drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
ADCC-enhanced monoclonal antibody targeting GPRC5D; Fc engineering increases binding to Fc gamma receptors (e.g., CD16) to activate NK cells and mediate antibody-dependent cellular cytotoxicity against malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CYTOTOXIC ANTIBODY
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fc-engineered monoclonal antibody that binds GPRC5D on malignant plasma cells and has increased affinity for Fcγ receptors (e.g., CD16) to more effectively recruit NK cells (and other FcγR+ effector cells), triggering antibody-dependent cellular cytotoxicity (and potentially ADCP/CDC) to kill myeloma cells.
drug_name
SAR446523
nct_id_drug_ref
NCT06630806